Company Milestone - Accuray Incorporated announced the completion of treatment for 100 patients using the Tomo® C Radiation Treatment Delivery System at Shandong Cancer Hospital and Institute, marking a significant milestone for the company in addressing the underserved Chinese radiation therapy market [1] - The Tomo C System, developed through the CNNC-Accuray joint venture, has expanded clinical capabilities and enabled potentially curative treatment for more cancer patients in China [1] Market Opportunity - The number of new cancer cases in China is expected to increase by 47% to 7.1 million in 2045, up from 4.8 million in 2022, highlighting the growing demand for advanced radiotherapy technology [2] - The Tomo C System is designed to meet the needs of the underserved Chinese radiation therapy market, with the potential to significantly increase treatment capacity and improve patient outcomes [1][5] Product Impact - The Tomo C System, based on the helical TomoTherapy® platform, enables the treatment of an average of 95 patient fractions per day, significantly increasing the hospital's capacity to provide innovative and effective cancer care [5] - The system integrates helical imaging, advanced treatment planning, and centralized data management to facilitate fast, ultra-precise treatments, allowing more patients to receive care each day [5] Strategic Collaboration - Shandong Cancer Hospital and Institute, a top cancer care center in China, serves over 400,000 patients annually and collaborates with global leaders such as MD Anderson Cancer Center, reinforcing its commitment to innovation and excellence in cancer treatment [4] - The introduction of the Tomo C System expands Accuray's product portfolio in China and reinforces its commitment to providing advanced tools for precision radiotherapy [4][5] Leadership Perspective - Suzanne Winter, President and CEO of Accuray, emphasized the system's ability to treat a wide range of cancer types and its potential to meaningfully increase treatment capacity, enabling more patients to receive care daily [3] - Prof. Yu, President of Shandong Cancer Hospital, highlighted the transformative impact of the TomoTherapy platform and the Tomo C System's role in advancing precision radiotherapy and supporting the "Healthy China Initiative" [5]

MADISON, Wis., Jan. 22, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2025, ended December 31, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on February 5, 2025.The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one wee ...

MADISON, Wis., Jan. 21, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Leonel Peralta is joining the company as Senior Vice President, Chief Operations Officer, effective February 3, 2025. Mr. Peralta will be responsible for leading worldwide manufacturing operations including driving alignment of operations with corporate business goals, maximizing supply chain profitability and efficiency, and ensuring processes support best-in-class customer service. He will report to Accur ...

Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher."Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth po ...

Accuray Incorporated (ARAY) recently announced that its Radixact SynC System and CyberKnife S7 System have been approved by the Chinese National Medical Products Administration. These approvals are likely to enable medical care teams to provide patients in China with the most advanced Accuray radiation therapy solutions.The CyberKnife S7 System is the latest generation CyberKnife platform, and the introduction of the Radixact SynC System marks the first approval in the country for the ClearRT kVCT imaging a ...

Company Announcements - Accuray Incorporated announced the approval of its Radixact SynC™ System and CyberKnife® S7™ System by the Chinese National Medical Products Administration (NMPA), enabling the provision of advanced radiation therapy solutions in China [9] - The CyberKnife S7 System is the latest generation CyberKnife platform, and the Radixact SynC System marks the first approval in China for ClearRT® kVCT imaging and Synchrony® real-time adaptive delivery technology on the Radixact System [9] Product Innovations - The Radixact SynC System features a helical design that delivers precise radiation doses continuously from multiple 360-degree rotations around the patient, minimizing dose to healthy tissue [4] - ClearRT is a helical kVCT fan-beam integrated imaging solution for the Radixact System, providing diagnostic-like quality CT images for high confidence in patient set-up and registration steps [5] - The CyberKnife S7 System delivers ultra-hypofractionated radiation therapy, completing treatments in 1 to 5 outpatient sessions compared to conventional 30-40 sessions, benefiting patients unable to travel for extended periods [6] - The CyberKnife S7 System is a robotic, non-invasive radiosurgery device capable of treating tumors with sub-millimetric accuracy in as little as 15 minutes, enabling precise radiation treatments for more patients daily [12] Market Strategy and Growth - The company aims to expand patient access in China by offering unique solutions, addressing the significant demand for radiotherapy treatments, with an estimated need for approximately 2,000 systems over the next five years [10] - The Radixact SynC System is the only helical delivery device in China with Synchrony real-time target tracking and correction technology, enhancing precision for tumors affected by bodily processes or patient movement [11] Leadership and Vision - Suzanne Winter, president and CEO of Accuray, expressed enthusiasm about the timing of the approvals, highlighting the introduction of the Tomo C System and the potential to address the needs of the largest market segment in China [3] - The company is dedicated to continuous innovation in radiation therapy for oncology and neuro-radiosurgery, partnering with clinicians to empower patients to return to their lives faster [7]

Accuray Incorporated (ARAY) is well-poised for growth in the coming quarters, courtesy of continued robust demand for its products. The optimism, led by robust international performance in the first quarter of fiscal 2025 and potential in the Radiosurgery Market, is expected to contribute further. However, reimbursement uncertainties and macroeconomic instability are concerning.This Zacks Rank #2 (Buy) company has gained 28.2% in the year-to-date period compared with 1.6% growth of the industry. The S&P 500 ...

The wait for real acceleration in revenue at Accuray (NASDAQ: ARAY ) increasingly feels like Waiting for Godot, as the company has been trying to sell investors on the China opportunity for years, and yet material revenue accelerationAnalyst’s Disclosure: I/we have a beneficial long position in the shares of ARAY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). ...

Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher."Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves a ...

The MedTech sector faced considerable challenges in 2024, making it a difficult year for investors. In the year, the slow growth of the global economy drew a lot of widespread attention. The year was also marked by significant elections around the world. As per World Economic Forum insights, the U.S. presidential race had an immediate effect on the global economy, with shares hitting record highs and the dollar rising against many currencies. Concerns about the global economic outlook have negatively affect ...